Advertisement
Search for

Volume 4, Issue 12, Pages 1440-1444 (December 2006)


View previous. 16 of 36 View next.

A Patient With Autoimmune Liver Disease on Steroids: Screening and Treatment of Bone Disease

William D. LeslieCorresponding Author Informationemail address

A 38-year-old woman presented with clinical and biochemical features of acute hepatitis. A tentative diagnosis of type 1 autoimmune hepatitis was made on the basis of positive autoantibodies (antinuclear and anti-smooth muscle), hypergammaglobulinemia, and hypocomplementemia. She was started on oral prednisone 40 mg/day, tapered over the subsequent 12 weeks to a maintenance dose of 7.5 mg/day. Azathioprine 100 mg/day then was introduced for its steroid-sparing effect, and she was started on vitamin D and calcium supplements. Her bone density (after 18 months of treatment) revealed a spine Z-score of −1.2 and a hip Z-score of −.8. She has never broken any bones, does not smoke, takes oral contraceptives, and has no other major risk factors for osteoporosis. What is the interpretation of the bone density Z-scores? How can this patient’s fracture risk be minimized, and how should she be monitored?

Department of Medicine, St. Boniface General Hospital, Winnipeg, Manitoba, Canada

Corresponding Author InformationAddress requests for reprints to: William D. Leslie, MD, MSc, Department of Medicine (C5121), St. Boniface General Hospital, 409 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6. fax: (204) 237-2007.

 In the past 5 years William D. Leslie has received speaker fees, research honoraria, and unrestricted research grants from Merck Frosst Canada Ltd. (the manufacturer of alendronate); research honoraria and unrestricted educational grants from Sanofi-Aventis and Proctor & Gamble Pharmaceuticals Canada, Inc. (the manufacturer of risedronate).

PII: S1542-3565(06)00950-5

doi:10.1016/j.cgh.2006.09.022


View previous. 16 of 36 View next.

Advertisement